[{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Niacin","moa":"||VLDL\/LDL synthesis","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved FDF","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Zydus Lifesciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Zydus Lifesciences \/ Inapplicable"},{"orgOrder":0,"company":"Hoskinson Health and Wellness Clinic","sponsor":"Buck Institute for Research on Aging | University of Wyoming","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Vitamin B1","moa":"||Bacterial Pyruvate decarboxylase (Bact aceE)","graph1":"Endocrinology","graph2":"Phase I","graph3":"Hoskinson Health and Wellness Clinic","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Hoskinson Health and Wellness Clinic \/ Buck Institute for Research on Aging | University of Wyoming","highestDevelopmentStatusID":"6","companyTruncated":"Hoskinson Health and Wellness Clinic \/ Buck Institute for Research on Aging | University of Wyoming"},{"orgOrder":0,"company":"Antengene","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"ATG-019","moa":"||PAK4","graph1":"Oncology","graph2":"Phase I","graph3":"Antengene","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Antengene \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Antengene \/ Inapplicable"},{"orgOrder":0,"company":"AronPharma Sp. z o. o.","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Plant Extract\/Herbal","year":"2023","type":"Inapplicable","leadProduct":"Cetraria Islandica","moa":"||Undisclosed","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"AronPharma Sp. z o. o.","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AronPharma Sp. z o. o. \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"AronPharma Sp. z o. o. \/ Inapplicable"},{"orgOrder":0,"company":"Oriflame Cosmetics AB","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"","productType":"Probiotic","year":"2022","type":"Inapplicable","leadProduct":"Berry Extract","moa":"||Immune","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Oriflame Cosmetics AB","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oriflame Cosmetics AB \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Oriflame Cosmetics AB \/ Inapplicable"},{"orgOrder":0,"company":"VIST","sponsor":"Slovenian Research and Innovation Agency | Tosla d.o.o.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Ashwagandha Root Extract","moa":"||Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"VIST","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VIST \/ Slovenian Research and Innovation Agency | Tosla d.o.o.","highestDevelopmentStatusID":"1","companyTruncated":"VIST \/ Slovenian Research and Innovation Agency | Tosla d.o.o."}]

Find Clinical Drug Pipeline Developments & Deals for Vitamin B3, Niacinamide, Nicotinic acid, Niacin

Vitamin B3, Niacinamide, Nicotinic acid, Niacin
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Vitamin B3, Niacinamide, Nicotinic acid, Niacin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

23 API Suppliers, 9 USDMF, 3 CEP/COS, 5 EU WC, 2 KDMF, 4 NDC API, 12 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

86 FDF Dossiers, 57 FDA Orange Book, 5 Europe, 1 Canada, 2 South Africa, 21 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET, EXTENDED RELEASE;ORAL - 1GM **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 500MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 750MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

2 EUROAPI, 1 Minakem, 3 Evonik, 13 Rochem International Inc, 23 SPI Pharma, 21 DKSH, 2 Pharm-RX Chemical, 6 Boai NKY Pharmaceuticals Ltd, 8 Gangwal Healthcare, 10 Nanjing Well Pharmaceutical, 1 Shanghai Minbiotech, 2 Pfanstiehl, 4 ACG Worldwide, 11 Actylis, 2 Aeon Procare, 1 Alcedo Pharmachem, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Ashland, 36 BASF, 1 Bioplus Life Sciences, 4 CD Formulation, 2 Clariant, 15 Corel Pharma Chem, 5 DFE Pharma, 1 Esteem Industries, 2 Finar, 13 Gangwal Chemicals, 9 Ideal Cures, 4 Ingredion Pharma Solutions, 22 Kerry, 3 Keval Exports, 5 Kima Chemical, 6 Lonza Capsugel, 19 Microlex e.U, 1 Nanjing Bold Chemical, 3 Nitika Pharmaceutical Specialities, 2 Nomisma Healthcare, 3 Novo Excipients, 3 Pharmatrans-Sanaq, 11 Pluviaendo, 3 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 35 Roquette, 17 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 3 Shijiazhuang Huaxu Pharmaceutical, 10 Sigachi Industries, 3 Silverline Chemicals, 4 The Dow Chemical Company, 2 Ulanqab Kema New Material, 2 Valens Pharmachem, 3 Vasa Pharmachem, 2 Zhejiang Huakang Pharmaceutical

EXCIPIENTS BY APPLICATIONS

97 Fillers, Diluents & Binders, 71 Coating Systems & Additives, 55 Thickeners and Stabilizers, 42 Solubilizers, 40 Controlled & Modified Release, 40 Taste Masking, 38 Direct Compression, 33 Granulation, 33 Topical, 29 Parenteral, 29 Film Formers & Plasticizers, 27 Lubricants & Glidants, 25 Disintegrants & Superdisintegrants, 24 Chewable & Orodispersible Aids, 17 Rheology Modifiers, 16 Co-Processed Excipients, 13 Emulsifying Agents, 10 API Stability Enhancers, 9 Empty Capsules, 7 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules, 1 Soft Gelatin

DIGITAL CONTENT

16 News #PharmaBuzz

16 News #PharmaBuzz

GLOBAL SALES INFORMATION

10 US Medicaid Prescriptions, 11 Regulatory FDF Prices

MARKET PLACE

18 APIs, 1 Intermediates

PATENTS & EXCLUSIVITIES

12 Health Canada Patents

12 Health Canada Patents

REF. STANDARDS & IMPURITIES

2 EDQM, 1 USP, 2 JP, 2 Others

ANALYTICAL

1 BioAnalytical Methods

1 BioAnalytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Alirocumab,Atorvastatin,Simvastatin,Fluvastatin,Pravastatin,Lovastatin,Rosuvastatin Calcium,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholester...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

April 27, 2018

Lead Product(s) : Alirocumab,Atorvastatin,Simvastatin,Fluvastatin,Pravastatin,Lovastatin,Rosuvastatin Calcium,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Alirocumab,Rosuvastatin Calcium,Atorvastatin,Simvastatin,Pravastatin,Lovastatin,Fluvastatin,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholest...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

April 27, 2018

Lead Product(s) : Alirocumab,Rosuvastatin Calcium,Atorvastatin,Simvastatin,Pravastatin,Lovastatin,Fluvastatin,Ezetimibe,Cholestyramine,Niacin,Fenofibrate,Omega-3

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase III

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Sanofi

France

ChemOutsourcing

Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

Lead Product(s) : Alirocumab,Ezetimibe,Cholestyramine,Fenofibrate,Omega-3,Niacin

Therapeutic Area : Cardiology/Vascular Diseases

Study Phase : Phase II

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents Wit...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Antibody

Upfront Cash : Inapplicable

September 07, 2016

Lead Product(s) : Alirocumab,Ezetimibe,Cholestyramine,Fenofibrate,Omega-3,Niacin

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Phase II

Sponsor : Regeneron Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Sanofi Company Banner

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

04

Zydus Lifesciences

India

EPSC

Not Confirmed

05

Hoskinson Health and Wellness Clinic

Country

EPSC

Not Confirmed

06

VIST

Country

EPSC

Not Confirmed

07

AronPharma Sp. z o. o.

Country

EPSC

Not Confirmed

08

Oriflame Cosmetics AB

Country

EPSC

Not Confirmed

09

Antengene

China

EPSC

Not Confirmed

10

University of Pennsylvania

Country

EPSC

Not Confirmed

1
2
3